Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.

Michelle Xiaoyan Zhang net worth and biography

Michelle Zhang Biography and Net Worth

Insider of Ikena Oncology

Michelle Zhang, Ph.D., joined Ikena (then Kyn Therapeutics) in 2016 as Vice President, Research and Development and was later promoted to Senior Vice President, Translational Research and Early Development. At Ikena, she has guided critical progress of the company’s pipeline programs to clinical studies. Dr. Zhang has over 20 years of oncology drug discovery and development experience in biotech as an entrepreneur in residence at Atlas Venture as well as at Curis, Inc. and BioMed Valley Discoveries, and in pharma at Novartis Institutes for Biomedical Research. Her R&D expertise spans across small molecule, antibody, antibody-drug-conjugate, protein and radiopharmaceutical therapeutic and diagnostic modalities. She has led numerous programs from early discovery, translational research and non-clinical evaluations into clinical development. Dr. Zhang received her Ph.D. in Biochemistry from Harvard University.

How do I contact Michelle Xiaoyan Zhang?: The corporate mailing address for Dr. Zhang and other Ikena Oncology executives is 645 SUMMER STREET SUITE 101, BOSTON MA, 02210. Ikena Oncology can also be reached via phone at 857-273-8343 and via email at [email protected]. Learn More on Michelle Xiaoyan Zhang's contact information.
Has Michelle Xiaoyan Zhang been buying or selling shares of Ikena Oncology?: Michelle Xiaoyan Zhang has not been actively trading shares of Ikena Oncology during the last ninety days. Most recently, Xiaoyan Michelle Zhang sold 36 shares of the business's stock in a transaction on Monday, January 10th. The shares were sold at an average price of $12.00, for a transaction totalling $432.00. Learn More on Michelle Xiaoyan Zhang's trading history.
Who are Ikena Oncology's active insiders?: Ikena Oncology's insider roster includes Jean-Francois Formela (Director), and Michelle Zhang (Insider). Learn More on Ikena Oncology's active insiders.

Michelle Xiaoyan Zhang Insider Trading History at Ikena Oncology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/10/2022	Sell	36	$12.00	$432.00
12/10/2021	Sell	1,000	$14.76	$14,760.00

Michelle Xiaoyan Zhang Buying and Selling Activity at Ikena Oncology

Ikena Oncology Company Overview

Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $1.53

$1.51

$1.71

50 Day Range

MA: $1.69

$1.55

$1.76

2 Week Range

Now: $1.53

$1.22

$2.29

Volume

582,522 shs

Average Volume

251,510 shs

Market Capitalization

$73.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.49

AI breakthrough about to upend industry

From Porter & Company | Ad

I urge you to watch it now.